Bextra Withdrawal Costs Pfizer $1.28 Bil. In First Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer will have to take charges to write off assets relating to the withdrawal of the COX-2 inhibitor in addition to $71 mil. in expected product returns. Pfizer has revised its April 5 guidance downward to reflect the withdrawal.
You may also be interested in...
Bextra Settlement Coming Soon: Industry Should Brace For Impact
Pfizer's pending $2.3 billion settlement of an investigation into the promotion of Bextra (valdecoxib) sets a new record for a pharma company's liability in a health care fraud case, and begs the question of how big the political liability facing the industry will be as the latest wave of marketing cases reaches settlement
Bextra Settlement Coming Soon: Industry Should Brace For Impact
Pfizer's pending $2.3 billion settlement of an investigation into the promotion of Bextra (valdecoxib) sets a new record for a pharma company's liability in a health care fraud case, and begs the question of how big the political liability facing the industry will be as the latest wave of marketing cases reaches settlement
Bextra $2.3 Bil. Charge For Pfizer Off-Label Settlement Mars Pre-Wyeth Earnings Report
Pfizer’s proposed $2.3 bil. agreement to resolve Justice Department investigation would be largest pharma settlement ever – not that anyone will notice in context of the $68 bil. Wyeth deal.